{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:13:55Z","timestamp":1791357235829,"version":"4.3.1"},"reference-count":24,"publisher":"Walter de Gruyter GmbH","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec id=\"j_dmpt-2018-0019_s_999\">\n<jats:title id=\"d212253e11066\">Background<\/jats:title>\n<jats:p>Bromodihydrochlorophenylbenzodiazepine (Phenazepam<jats:sup>\u00ae<\/jats:sup>) is used in the therapy of anxiety disorders in patients with alcohol dependence. However, Phenazepam therapy often turns out to be ineffective, and some patients develop dose-related adverse drug reactions (ADR): severe sedation, dizziness, headache, dyspepsia, falling, etc. That ensures the effectiveness of this category of patients. Despite the popularity of Phenazepam<jats:sup>\u00ae<\/jats:sup> as an anxiolytic drug, there is currently no accurate data on its biotransformation, as well as the effect of polymorphism of a gene on the efficacy and safety of bromodihydrochlorophenylbenzodiazepine in patients. The aim of our study was to study the effect of the polymorphism of the <jats:italic>CYP2C19<\/jats:italic> gene on the efficacy and safety index of Phenazepam<jats:sup>\u00ae<\/jats:sup> for patients with anxiety disorders, using algorithms for optimizing the therapy of Phenazepam<jats:sup>\u00ae<\/jats:sup> to reduce the risk of pharmacological resistance and increase the effectiveness of therapy.<\/jats:p><\/jats:sec>\n<jats:sec id=\"j_dmpt-2018-0019_s_998\">\n<jats:title id=\"d212253e11089\">Methods<\/jats:title>\n<jats:p>The study was conducted on 86 Russian patients suffering from alcohol dependence. Patients with trauma anxiety disorders received bromdihydrochlorphenylbenzodiazepine in tablets at a dose of 4.0 [2.0; 6.0] mg per day for 5 days. Genotyping was carried out by the method of polymer chain reaction in real time with allele-specific hybridization. Efficiency and safety assessment was carried out using psychometric scales and scales of Hospital Anxiety and Depression Scale (HADS) severity scores.<\/jats:p><\/jats:sec>\n<jats:sec id=\"j_dmpt-2018-0019_s_997\">\n<jats:title id=\"d212253e11097\">Results<\/jats:title>\n<jats:p>Based on the results of the study, statistically significant differences in the number of scores on the scale of HADS severity of <jats:italic>CYP2C19<\/jats:italic> CT on the third day of therapy were the following: (CC) 10.00 [9.00; 11.00], (CT) 14.00 [13.00; 16.00], (TT) 18.00 [17.00; 19.00], p=0.00, and also on the fifth day: (CC) 6.00 [5.00; 7.00], (CT) 17.50 [16.25; 19.75], (TT) 22.50 [20.00; 24.00], p=0.00. ADRs in patients with different genotypes for this polymorphic marker did not differ.<\/jats:p><\/jats:sec>\n<jats:sec id=\"j_dmpt-2018-0019_s_996\">\n<jats:title id=\"d212253e11108\">Conclusions<\/jats:title>\n<jats:p>Thus, it has been shown that the polymorphism of the <jats:italic>CYP2C19<\/jats:italic> gene may influence the effectiveness indices of Phenazepam therapy in patients with anxiety disorders comorbid with alcohol dependence. This should be taken into account in the appointment of this drug in this way in order to increase effectiveness of therapy and improve the quality of life.<\/jats:p><\/jats:sec>","DOI":"10.1515\/dmpt-2018-0019","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T09:01:43Z","timestamp":1539680503000},"page":"187-194","source":"Crossref","is-referenced-by-count":7,"title":["Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder"],"prefix":"10.1515","volume":"33","author":[{"given":"Michael S.","family":"Zastrozhin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6121-290X","authenticated-orcid":false,"given":"Anastasiya P.","family":"Antonenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena V.","family":"Nesterenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla I.","family":"Seyfullaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violetta R.","family":"Mustafina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonina P.","family":"Esakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena A.","family":"Grishina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandr S.","family":"Sorokin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin Yu.","family":"Skryabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmila M.","family":"Savchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny A.","family":"Bryun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry A.","family":"Sychev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","reference":[{"key":"ref231","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","year":"1959","journal-title":"Brit J Med Psychol"},{"key":"ref91","first-page":"28","article-title":"The Clinical Global Impressions scale: applying a research tool in clinical practice","volume":"4","year":"2007","journal-title":"Psychiatry"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.4103\/0019-5545.196975","article-title":"Clinical practice guidelines for the management of generalised anxiety disorder (GAD) and panic disorder (PD)","volume":"59","year":"2017","journal-title":"Indian J Psychiat"},{"key":"ref61","first-page":"335","article-title":"Midazolam and other benzodiazepines","year":"2008","journal-title":"Handb Exp Pharmacol"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","year":"1959","journal-title":"Brit J Med Psychol"},{"key":"ref251","first-page":"1","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","year":"1987","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-0404.2008.01004.x","article-title":"Benzodiazepines in epilepsy: pharmacology and pharmacokinetics","volume":"118","year":"2008","journal-title":"Acta Neurol Scand"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.drugalcdep.2005.04.011","article-title":"Substance-dependent patients with and without social anxiety disorder: occurrence and clinical differences. A study of a consecutive sample of alcohol-dependent and poly-substance- dependent patients treated in two counties in Norway","volume":"80","year":"2005","journal-title":"Drug Alcohol Depend"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.addbeh.2009.07.002","article-title":"Comorbidity of generalized anxiety disorder and alcohol use disorders among individuals seeking outpatient substance abuse treatment","volume":"35","year":"2010","journal-title":"Addict Behav"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.drugalcdep.2005.04.011","article-title":"Substance-dependent patients with and without social anxiety disorder: occurrence and clinical differences. A study of a consecutive sample of alcohol-dependent and poly-substance- dependent patients treated in two counties in Norway","volume":"80","year":"2005","journal-title":"Drug Alcohol Depend"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/archpsyc.61.8.807","article-title":"Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on alcohol and related conditions","volume":"61","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/j.1530-0277.1999.tb04349.x","article-title":"Psychometric properties of the Penn Alcohol Craving Scale","volume":"23","year":"1999","journal-title":"Alcohol Clin Exp Res"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.addbeh.2009.07.002","article-title":"Comorbidity of generalized anxiety disorder and alcohol use disorders among individuals seeking outpatient substance abuse treatment","volume":"35","year":"2010","journal-title":"Addict Behav"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/j.1530-0277.1999.tb04349.x","article-title":"Psychometric properties of the Penn Alcohol Craving Scale","volume":"23","year":"1999","journal-title":"Alcohol Clin Exp Res"},{"key":"ref221","first-page":"28","article-title":"The Clinical Global Impressions scale: applying a research tool in clinical practice","volume":"4","year":"2007","journal-title":"Psychiatry"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-0404.2008.01004.x","article-title":"Benzodiazepines in epilepsy: pharmacology and pharmacokinetics","volume":"118","year":"2008","journal-title":"Acta Neurol Scand"},{"key":"ref191","first-page":"335","article-title":"Midazolam and other benzodiazepines","year":"2008","journal-title":"Handb Exp Pharmacol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/j.1360-0443.1997.tb02848.x","article-title":"The life-time rates of three major mood disorders and four major anxiety disorders in alcoholics and controls","volume":"92","year":"1997","journal-title":"Addiction"},{"key":"ref121","first-page":"1","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","year":"1987","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/j.1360-0443.1997.tb02848.x","article-title":"The life-time rates of three major mood disorders and four major anxiety disorders in alcoholics and controls","volume":"92","year":"1997","journal-title":"Addiction"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/archpsyc.61.8.807","article-title":"Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on alcohol and related conditions","volume":"61","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.4103\/0019-5545.196975","article-title":"Clinical practice guidelines for the management of generalised anxiety disorder (GAD) and panic disorder (PD)","volume":"59","year":"2017","journal-title":"Indian J Psychiat"}],"container-title":["Drug Metabolism and Personalized Therapy"],"original-title":[],"link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/dmdi.2018.33.issue-4\/dmpt-2018-0019\/dmpt-2018-0019.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/dmpt-2018-0019\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T21:52:02Z","timestamp":1619041922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/dmpt-2018-0019\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,19]]},"references-count":24,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1515\/dmpt-2018-0019","relation":{},"ISSN":["2363-8915","2363-8907"],"issn-type":[{"value":"2363-8915","type":"electronic"},{"value":"2363-8907","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12,19]]}}}